Marker Therapeutics - MRKR Stock Forecast, Price & News

0 analysts have issued 1-year target prices for Marker Therapeutics' stock. Their MRKR share price forecasts range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for MRKR or view top-rated stocks among Wall Street analysts.

Marker Therapeutics' stock was trading at $0.2659 on January 1st, 2023. Since then, MRKR shares have increased by 351.3% and is now trading at $1.20.
View the best growth stocks for 2023 here.

Marker Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 65,400 shares, an increase of 64.3% from the February 13th total of 39,800 shares. Based on an average daily trading volume, of 38,500 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the shares of the company are sold short.
View Marker Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our MRKR earnings forecast.

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 110.00% and a negative net margin of 515.88%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.30%), Millennium Management LLC (2.03%), Renaissance Technologies LLC (1.95%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends.

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRKR stock can currently be purchased for approximately $1.20.

Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $10.03 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.